Trastuzumab Deruxtecan 100MG Injection is a HER2-targeted antibody-drug conjugate (ADC) used for selected HER2-related cancers. The 100MG presentation is supplied as a powder for intravenous infusion and must be administered by qualified healthcare professionals.
Cordium Pharmaceuticals Pvt Ltd is an India-based pharmaceutical exporter supporting eligible international buyers with pharmaceutical sourcing and export coordination.
Trastuzumab Deruxtecan 100MG Injection Supply
Cordium Pharmaceuticals Pvt Ltd provides supply support for eligible hospitals, oncology centers, pharmaceutical distributors and authorized healthcare buyers in:
- USA: Washington, New York & California
- UAE: Dubai & Abu Dhabi
- UK: London, Manchester & Birmingham
- South Africa: Johannesburg, Cape Town & Durban
Availability, prescription requirements and import permissions vary by country. Buyers should comply with applicable local regulations.
Uses of Trastuzumab Deruxtecan
Depending on the approved indication, trastuzumab deruxtecan may be used for selected:
- HER2-positive breast cancer
- HER2-low and HER2-ultralow breast cancer
- HER2-mutant non-small cell lung cancer
- HER2-positive gastric or gastroesophageal junction cancer
- Certain HER2-positive solid tumors
Current UK product information lists multiple approved indications and requires appropriate HER2 assessment for relevant indications.
Dosage & Administration
The 100MG refers to the vial strength, not necessarily the patient's individual dose.
For several approved indications, the recommended dose is 5.4 mg/kg intravenously every 3 weeks. Certain gastric cancer indications use 6.4 mg/kg every 3 weeks. Treatment should be prescribed and administered under specialist medical supervision.
Benefits
- HER2-targeted oncology treatment
- Antibody-drug conjugate technology
- Used for multiple approved HER2-related cancers
- Suitable for selected patients according to clinical indication
- International pharmaceutical sourcing support through Cordium Pharmaceuticals
Important Safety Information
Potential adverse effects include nausea, vomiting, fatigue, decreased appetite, low blood-cell counts and gastrointestinal symptoms.
A major safety concern is interstitial lung disease/pneumonitis, which can be serious or fatal. Patients should promptly report cough, shortness of breath, fever or new respiratory symptoms.
Why Choose Cordium Pharma?
1. Pharmaceutical Exporter from India
Cordium Pharmaceuticals Pvt Ltd supports international pharmaceutical procurement from India.
2. Hospital & Distributor Support
We cater to eligible hospitals, oncology centers, pharmaceutical distributors and authorized buyers.
3. International Supply Coordination
Support is available for orders destined for the USA, UK, UAE and South Africa, subject to local regulations.
4. Export Documentation Support
We assist eligible buyers with relevant commercial and export documentation as applicable.
5. Professional Shipment Coordination
Orders can be coordinated with appropriate pharmaceutical packaging and international shipping requirements.
6. Buyer-Focused Service
Cordium Pharma focuses on responsive communication and coordination for international pharmaceutical requirements.
Personal Import
Patients or individuals seeking Trastuzumab Deruxtecan for personal treatment should not self-medicate or arrange an import without checking local requirements. A valid prescription, medical documentation and applicable import authorization may be required. Hospitals and licensed healthcare providers are generally the appropriate route for oncology medicines.
FAQs
What is Trastuzumab Deruxtecan 100MG Injection?
It is a HER2-targeted antibody-drug conjugate used for selected cancer indications.
Who can order Trastuzumab Deruxtecan?
Eligible hospitals, oncology centers, authorized pharmaceutical distributors and healthcare buyers can inquire, subject to destination-country regulations.
Is 100MG the patient's dose?
No. 100MG is the vial presentation. The prescribed dose depends on the patient's body weight and cancer indication.
How often is it administered?
Many approved indications use an intravenous infusion every three weeks, although dosing varies by indication.
Can it be self-administered?
No. It is an intravenous oncology medicine that requires administration by trained healthcare professionals.
Does HER2 testing matter?
Yes. HER2 status or an activating HER2 mutation must be appropriately established for indications requiring it.
Does Cordium Pharma supply these locations?
Cordium Pharmaceuticals Pvt Ltd supports international supply inquiries for eligible buyers in Washington, New York, California, Dubai, Abu Dhabi, London, Manchester, Birmingham, Johannesburg, Cape Town and Durban, subject to applicable import and pharmaceutical regulations.
Conclusion
Trastuzumab Deruxtecan 100MG Injection is an advanced targeted oncology medicine used for selected HER2-related cancers. Cordium Pharmaceuticals Pvt Ltd provides pharmaceutical export and supply coordination from India for eligible hospitals, pharma distributors and authorized healthcare buyers across the USA, UAE, UK and South Africa.
Medical Disclaimer: This content is for informational and pharmaceutical procurement purposes only. Trastuzumab deruxtecan is a prescription oncology medicine and should be used only under qualified medical supervision.